In mice, polyIC greatly improved the ability of anti-programmed death-ligand 1 (PD-L1) therapy to clear or reduce melanomas and cancers of the lung and colon, and this effect was dependent on type 1 interferons [5]. This evidence concerns the gene CD274 and cancer.